Indies Pharma Jamaica Limited (JMSE:INDIES)
Jamaica · Delayed Price · Currency is JMD 2.830
+0.030 (1.07%)
At close: Dec 30, 2025
Indies Pharma Jamaica Income Statement
Financials in millions JMD. Fiscal year is November - October.
Millions JMD. Fiscal year is Nov - Oct.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | 2016 - 2020 |
| 1,127 | 1,159 | 1,055 | 937.28 | 846.83 | Upgrade | |
Revenue Growth (YoY) | -2.72% | 9.81% | 12.61% | 10.68% | 10.56% | Upgrade |
Cost of Revenue | 350.82 | 465.82 | 417.41 | 323.44 | 329.81 | Upgrade |
Gross Profit | 776.61 | 693.15 | 638.05 | 613.84 | 517.02 | Upgrade |
Selling, General & Admin | 524.11 | 354.55 | 308.57 | 273.53 | 244.65 | Upgrade |
Other Operating Expenses | -9.95 | -6.41 | -4.23 | 1.15 | 1.5 | Upgrade |
Operating Expenses | 514.16 | 410.01 | 367.82 | 332.13 | 299.61 | Upgrade |
Operating Income | 262.45 | 283.15 | 270.24 | 281.71 | 217.41 | Upgrade |
Interest Expense | -61.95 | -64.46 | -66.78 | -60.48 | -68.96 | Upgrade |
Interest & Investment Income | - | 1.6 | 1.46 | 0.95 | 4.84 | Upgrade |
Currency Exchange Gain (Loss) | 0.48 | 8.78 | 1.86 | -1.75 | 14.76 | Upgrade |
Other Non Operating Income (Expenses) | -0 | -2.95 | -3.29 | -2.22 | -2.59 | Upgrade |
EBT Excluding Unusual Items | 200.98 | 226.12 | 203.48 | 218.21 | 165.47 | Upgrade |
Gain (Loss) on Sale of Assets | - | 1.55 | 3.07 | 1.88 | 2.4 | Upgrade |
Pretax Income | 200.98 | 251.77 | 217.63 | 220.79 | 167.87 | Upgrade |
Income Tax Expense | 26.34 | - | - | - | - | Upgrade |
Net Income | 174.64 | 251.77 | 217.63 | 220.79 | 167.87 | Upgrade |
Net Income to Common | 174.64 | 251.77 | 217.63 | 220.79 | 167.87 | Upgrade |
Net Income Growth | -30.64% | 15.69% | -1.43% | 31.53% | -19.04% | Upgrade |
Shares Outstanding (Basic) | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade |
Shares Outstanding (Diluted) | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade |
Shares Change (YoY) | 0.04% | - | - | - | - | Upgrade |
EPS (Basic) | 0.13 | 0.19 | 0.16 | 0.17 | 0.13 | Upgrade |
EPS (Diluted) | 0.13 | 0.19 | 0.16 | 0.17 | 0.13 | Upgrade |
EPS Growth | -30.67% | 15.69% | -1.43% | 31.53% | -19.04% | Upgrade |
Free Cash Flow | 315.45 | 241.13 | 265.45 | 288.85 | 325.76 | Upgrade |
Free Cash Flow Per Share | 0.24 | 0.18 | 0.20 | 0.22 | 0.24 | Upgrade |
Dividend Per Share | - | 0.110 | 0.110 | 0.113 | 0.110 | Upgrade |
Dividend Growth | - | - | -2.66% | 2.73% | -21.43% | Upgrade |
Gross Margin | 68.88% | 59.81% | 60.45% | 65.49% | 61.05% | Upgrade |
Operating Margin | 23.28% | 24.43% | 25.60% | 30.06% | 25.67% | Upgrade |
Profit Margin | 15.49% | 21.72% | 20.62% | 23.56% | 19.82% | Upgrade |
Free Cash Flow Margin | 27.98% | 20.80% | 25.15% | 30.82% | 38.47% | Upgrade |
EBITDA | 291.42 | 303.32 | 289.13 | 300.95 | 233.54 | Upgrade |
EBITDA Margin | 25.85% | 26.17% | 27.39% | 32.11% | 27.58% | Upgrade |
D&A For EBITDA | 28.97 | 20.17 | 18.9 | 19.24 | 16.13 | Upgrade |
EBIT | 262.45 | 283.15 | 270.24 | 281.71 | 217.41 | Upgrade |
EBIT Margin | 23.28% | 24.43% | 25.60% | 30.06% | 25.67% | Upgrade |
Effective Tax Rate | 13.11% | - | - | - | - | Upgrade |
Advertising Expenses | - | 10.72 | 5.27 | 4.98 | 6.5 | Upgrade |
Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.